Publikationen, an denen er mitarbeitet Pedro Luis Sánchez Fernández (18)

2023

  1. Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk

    Cells, Vol. 12, Núm. 15

2022

  1. Cardiac magnetic resonance to detect different patterns of myocardial injury in patients receiving immune checkpoint inhibitors

    Revista Espanola de Cardiologia, Vol. 75, Núm. 3, pp. 266-269

2005

  1. Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer

    Anti-Cancer Drugs, Vol. 16, Núm. 1, pp. 77-82

2004

  1. Experiencia del Hospital Universitario de Salamanca en el tratamiento sistémico adyuvante del cáncer de mama locorregional. Resultados de un protocolo asistencial tras 7 años de seguimiento

    Oncologia, Vol. 27, Núm. 3, pp. 28-38

2003

  1. Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer: A multicenter phase II study

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 26, Núm. 2, pp. 127-131

1997

  1. Metastasis en vesicular biliar en un paciente con melanoma

    Neoplasia, Vol. 14, Núm. 1, pp. 32-34

  2. Quimioterapia y radioterapia secuenciales en el tratamiento del carcinoma de cabeza y cuello localmente avanzado. Resultados a largo plazo

    Acta Otorrinolaringologica Espanola, Vol. 48, Núm. 2, pp. 127-132

  3. Randomized trial of neoadjuvant chemotherapy with cisplatin plus 5- fluorouracil, with or without leurcovorin, in locally advanced head and neck cancer [1]

    Annals of Oncology

1996

  1. Do the conventional clinicopathologic parameters predict for response and survival in head and neck cancer patients undergoing neoadjuvant chemotherapy?

    Tumori, Vol. 82, Núm. 6, pp. 560-566

  2. Mediastinal mass following chemotherapy in patients with Ewing sarcoma and osteosarcoma

    Journal of Internal Medicine, Vol. 239, Núm. 5, pp. 457-460

  3. Neoadjuvant chemotherapy with continuous infusion of cisplatin and 5-fluorouracil, with or without leucovorin, for locally advanced nasopharyngeal carcinoma.

    The Journal of infusional chemotherapy, Vol. 6, Núm. 4, pp. 217-220

  4. QUIMIOTERAPIA NEOADYUVANTE CON CISPLATINO Y 5-FLUOROURACILO CON O SIN ACIDO FOLINICO COMO TRATAMIENTO DEL CARCINOMA DE CABEZA Y CUELLO LOCALMENTE AVANZADO. ESTUDIO EN FASE II

    Neoplasia, Vol. 13, Núm. 3, pp. 74-77

1995

  1. Four days' continuous infusion of cisplatin-5-fluorouracil and short daily infusion of high-dose leucovorin as induction chemotherapy for locally advanced head and neck cancer.

    The Journal of infusional chemotherapy, Vol. 5, Núm. 3, pp. 125-128

  2. Suspected extragonadal germ-cell cancer syndrome presenting with an orbital mass and elevation of serum CEA, CA19-9 and CA50 levels

    Tumori, Vol. 81, Núm. 5, pp. 378-380

1994

  1. Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil, both in continuous 96-hour infusion, in the treatment of locally advanced head and neck cancer

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 17, Núm. 1, pp. 6-9

1993

  1. Oat-cell carcinoma of primary location in the pericardium. A case report

    Tumori, Vol. 79, Núm. 2, pp. 144-146

1992

  1. Phase II study with the combination of mitomycin C, epirubicin and vincristine (MEV) as rescue treatment in previously treated metastatic breast cancer patients

    Libri Oncologici, Vol. 21, Núm. 3, pp. 179-182

1989

  1. Four‐day continuous infusion of cisplatin and 5‐fluorouracil in head and neck cancer

    Cancer, Vol. 63, Núm. 10, pp. 1927-1930